Capability
Portfolio & Indication Strategy
BridgeLine Translational's Portfolio & Indication Strategy scopes three allocation decisions: which indication to pursue for a therapeutic, which program to fund first across a pipeline, or which application a platform should deploy into first. Same scientific discipline as Competitive Intelligence, oriented at the choice instead of the field.
When to engage
Common engagements
Three situations where Portfolio & Indication Strategy engagements usually start.
For platforms and single-program teams
“Which indication should we pursue?”
A single therapeutic or platform with multiple potential applications. Each candidate is evaluated against unmet need, competitive density, regulatory precedent, model availability, and time to value. Output is a ranked list with rationale and the evidence behind it.
For multi-program biotechs
“Which program should we fund first?”
Each program evaluated head-to-head on scientific maturity, competitive position, regulatory clarity, capital efficiency, and time to value inflection. Output is an explicit prioritization with the rationale a board can defend.
For platform companies
“Where should we deploy the platform first?”
Each possible application evaluated for biological fit, competitive density, partner appetite, and capital required to a meaningful inflection. Output is a ranked sequence the team can build the operating plan around.
Three decisions a portfolio must make
Indication. Allocation. Where to deploy first.
Scored candidate list, head-to-head matrix, written rationale, and a decision framework the team can reuse.
Candidate list and scoring
- Every indication, program, or platform application in a named set
- Scored on unmet need, competitive density, regulatory precedent, and scientific feasibility
- Evidence citations next to every score
Head-to-head matrix
- Candidates compared on the same axes, not evaluated in isolation
- Explicit prioritization with defensible rationale
- Visual matrix ready for board and investor decks
Written rationale
- A memo laying out why the lead candidate is the lead
- What the runner-up would need for the ranking to change
- Which candidates to keep in the queue and which to drop
Decision framework for ongoing use
- The scoring axes and weightings as a team-owned template
- Instructions for adding new candidates against the same rubric
How the work runs
Phases
Scope shaped on the scoping call.
Scope
Agree on the candidate set, the decision in front of the team, and the axes that matter for the call.
Evidence build
Primary-source pull on each candidate: unmet need, competitive density, regulatory precedent, feasibility. Every claim sourced.
Evaluation
Head-to-head scoring. Draft the matrix and the written rationale. Flag gaps in the evidence explicitly.
Decision memo
Walk the team through the recommendation. Hand over the framework for ongoing use as new candidates emerge.
Who it's for
Audience
Platform companies
Platform technology with multiple applications. Lead-application selection and pipeline sequencing.
Multi-program biotechs
Multi-program pipelines under capital constraint. Prioritization for the next allocation decision.
Academic spinouts
Strong technology with broad therapeutic applicability. Lead-indication selection for the seed or Series A pitch.
FAQ
Frequently asked questions
§ / More capabilities
Other capabilities
Competitive Intelligence
Read the field. Study by study, with a source trail on every claim.
Read more →Preclinical Strategy
Build the plan. Study-by-study path from discovery through IND-enabling.
Read more →Investor/Partner Readiness
Prepare the package. Independent review of what investors and partners will see.
Read more →§ / Engage
Contact
BridgeLine Translational. A remote practice, serving biotech clients worldwide.